PremiumThe FlySavara price target lowered to $7 from $8 at Wells Fargo U.S. extends EU tariff deadline, Salesforce to acquire Informatica: Morning Buzz Savara Faces FDA Setback for MOLBREEVI Application PremiumThe FlySavara reports Q1 EPS (12c), consensus (13c) Savara announces encore presentations from Molgramostim Phase 3 IMPALA-2 trial Savara’s Strategic Advancements and Market Potential of Molbreevi: A Transformative Approach to aPAP Treatment PremiumRatingsSavara’s Innovative Testing and BLA Submission Drive Buy Rating Amid Market Growth Potential Savara Sets 2025 Executive Bonus Targets Savara Highlights MOLBREEVI’s Potential in Rare Disease Market 
